Live, oral vaccine for protection against Shigella dysenteriae serotype 1
    64.
    发明授权
    Live, oral vaccine for protection against Shigella dysenteriae serotype 1 有权
    用于保护痢疾志贺氏菌血清型1的活的口服疫苗

    公开(公告)号:US08968719B2

    公开(公告)日:2015-03-03

    申请号:US14145104

    申请日:2013-12-31

    Abstract: The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.

    Abstract translation: 本发明涉及包含核心型痢疾志贺氏菌血清型1型O特异性多糖(O-Ps)和编码O抗原生物合成的DNA的伤寒沙门氏菌Ty21a,所述DNA选自:a)任何一个中列出的DNA序列 的SEQ ID NO:1和2及其物种同系物; b)编码由SEQ ID NO:1和2中任一个编码的痢疾志贺氏菌血清型1多肽的DNA及其同源物; 和c)编码在中等严格条件下与(a)或(b)的DNA杂交的O抗原生物合成基因产物的DNA; 和相关序列,物质组合物,疫苗,使用方法和制备方法。

    Modified TNF-alpha molecules, DNA encoding such and vaccines comprising such modified TNF-alpha and DNA
    69.
    发明授权
    Modified TNF-alpha molecules, DNA encoding such and vaccines comprising such modified TNF-alpha and DNA 失效
    修饰的TNF-α分子,编码这样的DNA和包含这种修饰的TNF-α和DNA的疫苗

    公开(公告)号:US07118750B1

    公开(公告)日:2006-10-10

    申请号:US09060294

    申请日:1998-04-15

    Abstract: A modified human TNFα molecule is capable of raising neutralizing antibodies towards unmodified human TNFα following administration of the modified TNFα to a human host, wherein one or more peptide fragments of the human TNFα molecule has been substituted by one or more peptides containing immunodominant T cell epitopes or a truncated form of the molecule containing the immunodominant epitope and one or both flanking regions of the human TNFα-molecule containing at least one TNFα B cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of any one of the strands of the front β-sheet, in any one of the connecting loops, or in any one of the B′, I, or D strands of the back β-sheet.

    Abstract translation: 在将修饰的TNFα施用于人宿主后,经修饰的人TNFα分子能够提供针对未修饰的人TNFα的中和抗体,其中人TNFα分子的一个或多个肽片段已被含有免疫优势T细胞表位的一种或多种肽取代 或包含免疫显性表位和含有至少一种TNFαb细胞表位的人TNFα分子的一个或两个侧翼区域的分子的截短形式,其中所述取代引入任何一条链的氨基酸序列的显着变化 在任何一个连接环中,或在背面β片中的任何一个B',I或D链中的前β片。

Patent Agency Ranking